Hematology: Non-Hodgkin lymphoma (B- and T-cell) — Chemotherapy (targeted therapy). Treatment
NHL treatment depends on a particular tumor type. To combat the most common B-cell lymphomas, the targeted chemotherapy drugs are widely used in recent years. These drugs focus on tumor cells without causing damage to healthy tissues. Timely therapy commencement allows achieving a complete remission in 70-80% of patients.
The use of chemotherapy requires an objective assessment of the patient's condition. To this end, s/he is prescribed:
- oncologist’s advice,
- complete blood count,
- blood chemistry,
- cytogenetic analysis.
Based on the case history and test findings, the physician makes a treatment decision.
The patient is hospitalized for 10 days to receive treatment. The drugs are administered daily in the form of infusion. In order to increase the treatment effectiveness, a combination of 5 to 6 cytostatics is used, the main of which is rituximab. This drug belongs to a class of monoclonal antibodies and provides a focused impact on B-lymphocytes.
An intensive therapy cycle may be accompanied by various side effects, so the patient remains under continuous surveillance. The nursing care is provided by the nursing staff of the clinic.
The patients commonly report:
- drop in blood pressure,
- increased susceptibility to infections.
The adverse symptoms are reversed by appropriate therapy (immunomodulators, antibiotics, blood transfusion, if required, and so on). The cost of medication is determined by the amount of therapeutic measures.
To prevent infectious complications, the patient is recommended to limit contacts with the outside world and to comply with strict hygiene requirements. After cycle completion, the patient is provided guidance for further therapy.Hide
Haven't found Your diagnosis yet?
Send an inquiry to get a cost estimate on: